Resources

ARC's comprehensive European Health Technology Assessments (HTA) Toolkit was produced to give information about how treatments are evaluated and approved for use in the various member state healthcare systems. The Toolkit guides patients and patient groups on how they can participate in the process to ensure that those treatments that are developed for their amyloidosis can be made available in their countries.

In this patient webinar, Dr. Heather Landau, a leading hematologist at Memorial Sloan Kettering Cancer Center, discusses current therapies, clinical trials, and symptom management strategies for patients with AL amyloidosis.

ARC-supported consensus best practice recommendations for the diagnosis of ATTR amyloidosis with polyneuropathy published in the Journal of Neurology, Circulation: Heart Failure.

Genetic counselors Emily Brown and Katelyn Swade provide an overview of the science of genetic testing. They also discuss importance of genetic counseling for hereditary ATTR patients and their families.

"Amyloidosis Research Consortium Cardiac Amyloidosis Survey: An International Analysis of the Diagnostic Journey in AL and ATTR Amyloidosis," was presented at the 23rd annual Heart Failure Society of America meeting from September 13-16, 2019 in Philadelphia, PA. This poster presents results from 745 patients and caregivers and highlights regional differences, changes over time, and how we can improve the diagnostic journey of amyloidosis patients.

ARC-supported consensus best practices guidelines for the diagnosis of cardiac ATTR amyloidosis published in the journal of the American Heart Association, Circulation: Heart Failure.

These practice points from the American Society of Nuclear Cardiology (ASNC) are to identify the critical components involved in performing (99m) Tc-PYP imaging for the evaluation of cardiac transthyretin amyloidosis (ATTR).

Presented in February 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Ronald M. Witteles, MD; Mazen Hanna, MD; and Martha Grogan, MD,